Dr. Qian Jiang: Reduced Dosage without Reducing Efficacy, Better Quality of Life for Patients

Dr. Qian Jiang: Reduced Dosage without Reducing Efficacy, Better Quality of Life for Patients

2024.01.15
From June 8th-11th, 2023, the 28th European Hematology Association (EHA) conference was held in Frankfurt, Germany. At the EHA meeting, Professor Jiang Qian's team from Peking University People's Hospital reported on the results of a study on reducing treatment doses for Chronic Myeloid Leukemia (CML) patients after achieving major molecular remission (abstract S158). During the conference, the "Tumor Watch" publication interviewed Dr. Qian Jiang, who elaborated on the current status of CML treatment, future prospects, and the initial intent and primary outcomes of the dosage reduction study.
2023 ASH丨Professor Jiang Qian: Discussing Drug Resistance in Chronic Myeloid Leukemia (CML) Treatment and the Value of Novel TKIs

2023 ASH丨Professor Jiang Qian: Discussing Drug Resistance in Chronic Myeloid Leukemia (CML) Treatment and the Value of Novel TKIs

2024.01.04
The 65th Annual Meeting of the American Society of Hematology (ASH) recently concluded, with significant contributions in the field of Chronic Myeloid Leukemia (CML) treatment. Professor Jiang Qian and her team from Peking University People's Hospital presented multiple studies, with abstracts 867 and 869 selected for oral presentations. These reports highlighted the potential of TGRX-678 and Olverembatinib in CML treatment and overcoming drug resistance. "Hematology Frontier" had the privilege of interviewing Professor Jiang Qian on these topics.
Dr. QianJiang: Reduced Dosage without Reducing Efficacy, Better Quality of Life for Patients

Dr. QianJiang: Reduced Dosage without Reducing Efficacy, Better Quality of Life for Patients

2023.10.12
From June 8th-11th, 2023, the 28th European Hematology Association (EHA) conference was held in Frankfurt, Germany. At the EHA meeting, Professor Jiang Qian's team from Peking University People's Hospital reported on the results of a study on reducing treatment doses for Chronic Myeloid Leukemia (CML) patients after achieving major molecular remission (abstract S158). During the conference, the "Tumor Watch" publication interviewed Dr. Qian Jiang, who elaborated on the current status of CML treatment, future prospects, and the initial intent and primary outcomes of the dosage reduction study.